Inherited Cancer Early Diagnosis (ICED) Study

Launched by ROYAL MARSDEN NHS FOUNDATION TRUST · Nov 30, 2023

Keywords

ClinConnect Summary

The Inherited Cancer Early Diagnosis (ICED) Study is a research trial aimed at finding new ways to detect cancer early in people who are at high risk due to specific genetic changes. This study focuses on individuals with certain inherited conditions, such as Li Fraumeni Syndrome and Lynch Syndrome, which can increase the likelihood of developing certain types of cancer. Researchers are collecting blood and urine samples to identify markers that could help spot cancer before symptoms appear.

To participate in this study, you need to be over 18 years old and not currently have active cancer. You must also have a known genetic change that is likely to lead to cancer, such as those found in specific genes like TP53 or MLH1. If you join the study, you will be asked to provide samples and may undergo some follow-up checks. This research is important because it could lead to better early detection methods for people at risk, ultimately improving treatment outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients over the age of 18 years old, with no active cancer
• • 2. Carriers of a pathogenic/likely pathogenic variant in any of the following genes: TP53, Mismatch Repair genes (MLH1, MSH2, MSH6, PMS2, EPCAM), PTEN, STK11 (Peutz-Jeghers syndrome), CDH1, APC, SMAD4, MUTYH\* (\*biallelic carriers).
• • 3. Able to consent to the study.
• Exclusion Criteria:
• • 1. Carriers of a variant associated with reduced penetrance (in the view of a geneticist) or a variant of uncertain significance.
• • 2. Patients with a malignancy diagnosed in the previous 5 years \[except non-melanomatous skin cancer or cervical carcinoma in situ (CIS)\].